Imatinib: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
* Marketed By: Novartis | * Marketed By: Novartis | ||
* Major Indication: Leukemia and Gastrointestinal Stromal [[Cancer|Tumors]] | * Major Indication: Leukemia and Gastrointestinal Stromal [[Cancer|Tumors]] | ||
* Drug Class: Receptor Tyrosine Kinase (Especially PDGFR & KIT) Inhibitor | * Drug Class: Receptor Tyrosine Kinase (Especially PDGFR, Abl & KIT) Inhibitor | ||
* Date of FDA Approval (Expiration): 2001 (2015) | * Date of FDA Approval (Expiration): 2001 (2015) | ||
* 2009 Global Sales: $3.9 Billion | * 2009 Global Sales: $3.9 Billion | ||
